Analytical Development for Viral Vectors, Oncolytic Viruses and Viral Vaccines
Our Analytical and Quality Control teams share a collective experience in 100+ gene therapies. We provide solutions from development to commercialization, navigating you through the new era of regulations for gene therapies. We are equipped to handle unique and challenging program requirements. Learn more about our analytical capabilities and leading edge technologies.
We develop and validate phase appropriate analytical methods for in-process monitoring and release testing, consistent with current regulatory guidelines.
Analytical Capabilities for Gene Therapy Products
Gene therapy products present new and unique analytical challenges, specifically around the detection of infectivity and approaches to determining the ratio of infectious to non-infectious particles. Our Global Virus Analytical Development and Quality Control teams are highly experienced in method development strategies needed for monitoring and release of viral products.
Summary of titer and quality analytics
- Capsid titer by ELISA
- Genome titer by ddPCR
- Purity by CE-SDS, HPLC
- Aggregation by HPLC
- TCID50 by cell based assay with ddPCR output
- Residual impurities
- Identity assays
- Safety and compendial methods
Process Development – Robust and Reliable
Learn more about Process Development for Viral Vectors
cGMP Production – Effective and Reliable
Learn more about cGMP Production for Cell and Gene Services
Drug Product – Convenient and Cost Effective
Learn more about Drug Product
Viral Vector Platforms – Triple Transfection Technology
Learn more about Viral Vector Platforms